{"id":"W2076869933","doi":"10.1007/s40273-014-0241-z","title":"Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline; Eli Lilly and Company","keywords":"Dabrafenib; Dacarbazine; Vemurafenib; Medicine; Oncology; Progression-free survival; Internal medicine; Hazard ratio; Metastatic melanoma; Melanoma; Cancer research; Overall survival; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003198531,0.0002477418,0.0005120258,0.0006260277,0.0007649495,0.001335417,0.0007452471,0.000552071,0.002916588],"category_scores_gemma":[0.003173938,0.0001817173,0.001024251,0.001566623,0.0004337651,0.0002695516,0.0004385528,0.0009010749,0.00009284965],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.06315782,"about_ca_system_score_gemma":0.045615,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9786546,"about_ca_topic_score_gemma":0.9876293,"domain_scores_codex":[0.9994208,0.0001078148,0.00003481648,0.00004785678,0.0001606686,0.0002281054],"domain_scores_gemma":[0.9983688,0.000228163,0.0002618477,0.00001673219,0.0003782653,0.0007462985],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01178821,0.0008655529,0.7902758,0.0007731606,0.001583427,0.001452455,0.0003503521,0.02819329,0.001234614,0.004381761,0.02997348,0.129128],"study_design_scores_gemma":[0.002213597,0.001032997,0.9557512,0.0003736412,0.001490506,0.0008663331,0.001514092,0.02476355,0.0005491709,0.0007554814,0.01059549,0.00009400939],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.965619,0.009235607,0.0001735325,0.01023829,0.0001317329,0.00009654115,0.004725686,0.00002837433,0.009751325],"genre_scores_gemma":[0.9948359,0.002418468,0.0001367705,0.0005480683,0.00003197472,0.00001349133,0.0008893504,0.000005874736,0.001120161],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06315782,"threshold_uncertainty_score":0.4582442,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01314990988160582,"score_gpt":0.2653310791335,"score_spread":0.2521811692518942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}